Results 11 to 20 of about 14,094 (223)

The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study

Medicines, 2022
Background and Objectives: This study aimed to investigate the changes in obesity severity, glucose metabolism, and body composition in patients with obesity and type 2 diabetes mellitus treated with glucagon-like peptide 1 receptor agonist (GLP1-RA ...
Yoshinori Ozeki, Takayuki Masaki, Akari Kamata, Shotaro Miyamoto, Yuichi Yoshida, Mitsuhiro Okamoto, Koro Gotoh, Hirotaka Shibata   +7 more
doaj   +1 more source

Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China

Frontiers in Pharmacology, 2023
Introduction: Oral semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) that improves glycated hemoglobin levels and body weight in patients with type 2 diabetes (T2DM).
Zhen Feng, Zhen Feng, Wai Kei Tong, Xinyue Zhang, Zhijia Tang   +4 more
doaj   +1 more source

Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study

Journal of Comparative Effectiveness Research, 2022
What is this summary about? This is a plain language summary of the STEP TEENS research study, which was originally published in the New England Journal of Medicine.
Daniel Weghuber, Klaus Boberg, Dan Hesse, Ole K Jeppesen, Rasmus Sørrig, Aaron S Kelly   +5 more
doaj   +1 more source

Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation

Frontiers in Endocrinology, 2021
Despite the benefits of early and effective glycemic control in the management of type 2 diabetes (T2D), achieving glycated hemoglobin (HbA1c) targets is challenging in some patients. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) provide effective
Juris J. Meier
doaj   +1 more source

Harnessing the Reactivity of Sulfinate Salts With Cystine: An Umpolung Approach to Residue‐Specific Peptide Modification

Angewandte Chemie, EarlyView.
While cysteine is widely employed as a nucleophilic handle for peptide modification, the electrophilicity of the oxidized form, cystine, is rarely exploited. This study describes a mild, photochemical coupling of sulfinate salts with peptide disulfides.
Joshua M. Hammond, Esteban Suárez‐Picado, Lena von Sydow, Hanna Bruss, Laurent Knerr, Magnus Johansson, Anaïs Noisier, Lara R. Malins   +7 more
wiley   +2 more sources

Effect of Semaglutide on Subclinical Atherosclerosis and Cardiometabolic Compensation: A Real-World Study in Patients with Type 2 Diabetes

Biomedicines, 2023
Background: Semaglutide is a recently approved glucagon-like peptide-1 receptor agonist. Several trials reported the protective effect of injectable semaglutide on cardiovascular (CV) risk by reducing major adverse cardiovascular events in type 2 ...
Angelo Maria Patti, Rosaria Vincenza Giglio, Alberto Allotta, Andreina Bruno, Tommaso Di Bella, Anca Pantea Stoian, Marcello Ciaccio, Manfredi Rizzo   +7 more
doaj   +1 more source

Multicomponent Stapling of Glucagon‐Like Peptide‐1 Enables Receptor‐Guided PROTAC Delivery

Angewandte Chemie, EarlyView.
We report a stapled glucagon‐like peptide‐1 (GLP‐1) analogue created via multicomponent tryptophan‐mediated Petasis reaction (TMPR). This strategy yields a stabilised peptide with superior helicity and improved potency. Conjugation to a bromodomain‐containing protein 4 (BRD4) degrader creates the first GLP‐1‐guided targeted protein degrader (PROTAC ...
Jan L. Venne, Sona Krajcovicova, Graeme Davies, Hannah Bolt, Jefferson Revell, David R. Spring   +5 more
wiley   +2 more sources

The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission

JCI Insight, 2023
Growing evidence indicates that the glucagon-like peptide-1 (GLP-1) system is involved in the neurobiology of addictive behaviors, and GLP-1 analogues may be used for the treatment of alcohol use disorder (AUD).
Vicky Chuong, Mehdi Farokhnia, Sophia Khom, Claire L. Pince, Sophie K. Elvig, Roman Vlkolinsky, Renata C.N. Marchette, George F. Koob, Marisa Roberto, Leandro F. Vendruscolo, Lorenzo Leggio   +10 more
doaj   +1 more source

The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study

Frontiers in Endocrinology
BackgroundWithdrawal of semaglutide is frequently followed by weight regain due to compensatory biological changes that prevent the maintenance of long-term weight loss. There are some studies implying that metformin might attenuate weight regain.
Mojca Jensterle, Mojca Jensterle, Simona Ferjan, Simona Ferjan, Andrej Janez, Andrej Janez   +5 more
doaj   +1 more source

Glucagon-Like Peptide-1 Receptor Agonist Semaglutide Improves Eating Behavior and Glycemic Control in Japanese Obese Type 2 Diabetic Patients

Metabolites, 2022
We evaluated time-course changes and the relationship between eating behavior and glycemic profile during the treatment of 34 obese type 2 diabetic patients with the glucagon-like peptide-1 receptor agonist (GLP1-RA) semaglutide.
Takayuki Masaki, Yoshinori Ozeki, Yuichi Yoshida, Mitsuhiro Okamoto, Shotaro Miyamoto, Koro Gotoh, Hirotaka Shibata   +6 more
doaj   +1 more source